Patents by Inventor John Lindbo
John Lindbo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12642203Abstract: A variants of the TM-2-2 protein, conferring recognition of the Movement Protein (MP) of the Tomato Brown Rugose Fruit Virus (ToBRFV), and wherein said variant comprises a tyrosine (Y), a phenylalanine (F) or a tryptophan (W) at the position corresponding to tyrosine 767 of the TM-2-2 protein and at least one of the following mutations: C848R, N822C, N822F, N822M, N822Y, N822W, N825H, N825K and N825T with respect to the TM-2-2 protein, potentially in combination with a F655L mutation. The present invention also relates to genetic sequences encoding such a variant protein, preferably to a mutated Tm-2-2 gene, and to plants, especially Solanum lycopersicum plants comprising in their genome the mutated gene conferring resistance to ToBRFV. The invention is also directed to parts of these plants, as well as progeny, and to the use of these sequences for providing ToBRFV resistance.Type: GrantFiled: December 3, 2021Date of Patent: June 2, 2026Assignee: VILMORIN & CIEInventor: John Lindbo
-
Publication number: 20240049668Abstract: A variants of the TM-2-2 protein, conferring recognition of the Movement Protein (MP) of the Tomato Brown Rugose Fruit Virus (ToBRFV), and wherein said variant comprises a tyrosine (Y), a phenylalanine (F) or a tryptophan (W) at the position corresponding to tyrosine 767 of the TM-2-2 protein and at least one of the following mutations: C848R, N822C, N822F, N822M, N822Y, N822W, N825H, N825K and N825T with respect to the TM-2-2 protein, potentially in combination with a F655L mutation. The present invention also relates to genetic sequences encoding such a variant protein, preferably to a mutated Tm-2-2 gene, and to plants, especially Solanum lycopersicum plants comprising in their genome the mutated gene conferring resistance to ToBRFV. The invention is also directed to parts of these plants, as well as progeny, and to the use of these sequences for providing ToBRFV resistance.Type: ApplicationFiled: December 3, 2021Publication date: February 15, 2024Applicant: VILMORIN & CIEInventor: John LINDBO
-
Patent number: 11845942Abstract: The present disclosure provides compositions, methods, and systems for targeted plant genome editing. In some embodiments, the present disclosure provides recombinant self-replicating RNAs derived from a plant virus vector, such as those derived from Tobacco Mosaic Virus (TMV). In some embodiments, the recombinant self-replicating RNAs direct the expression of both a CRISPR endonuclease and a guide RNA capable of directing sequence-specific binding of the CRISPR endonuclease to a target DNA in the genome of plant cell.Type: GrantFiled: June 7, 2018Date of Patent: December 19, 2023Assignee: Vilmorin & CieInventor: John Lindbo
-
Publication number: 20200199605Abstract: The present disclosure provides compositions, methods, and systems for targeted plant genome editing. In some embodiments, the present disclosure provides recombinant self-replicating RNAs derived from a plant virus vector, such as those derived from Tobacco Mosaic Virus (TMV). In some embodiments, the recombinant self-replicating RNAs direct the expression of both a CRISPR endonuclease and a guide RNA capable of directing sequence-specific binding of the CRISPR endonuclease to a target DNA in the genome of plant cell.Type: ApplicationFiled: June 7, 2018Publication date: June 25, 2020Inventor: John LINDBO
-
Publication number: 20080032346Abstract: We describe here an in vitro method of increasing complementarity in a heteroduplex polynucleotide sequence. The method uses annealing of opposite strands to form a polynucleotide duplex with mismatches. The heteroduplex polynucleotide is combined with an effective amount of enzymes having strand cleavage activity, 3? to 5? exonuclease activity, and polymerase activity, and allowing sufficient time for the percentage of complementarity to be increased within the heteroduplex. Not all heteroduplex polynucleotides will necessarily have all mismatches resolved to complementarity. The resulting polynucleotide is optionally ligated. Several variant polynucleotides result. At sites where either of the opposite strands has templated recoding in the other strand, the resulting percent complementarity of the heteroduplex polynucleotide sequence is increased. The parent polynucleotides need not be cleaved into fragments prior to annealing heterologous strands. Therefore, no reassembly is required.Type: ApplicationFiled: June 25, 2007Publication date: February 7, 2008Applicant: LARGE SCALE BIOLOGY CORPORATIONInventors: Hal Padgett, John Lindbo, Wayne Fitzmaurice
-
Publication number: 20060188991Abstract: Herein-described are various methods for making a vaccine that are made of re-assembled virus like particles (VLP). First, the VLPs are disassembled into encapsidation intermediate populations. Each encapsidation intermediate population undergoes, for instance, chemical conjugation of unique peptide or nucleic moieties to form separate populations. Thereafter, a predetermined amount of each of the several (one or more) different encapsidation intermediates from the different populations is mixed and joined, forming intact VLPs, surrounding a nucleic acid core, that are composed of different encapsidation intermediate such that the reassembled VLP displays more than one peptide or nucleic acid. The nucleic acid can function either as a scaffold alone or can be engineered for the expression of an immunomodulatory protein in a eukaryotic cell.Type: ApplicationFiled: April 24, 2006Publication date: August 24, 2006Inventors: Alison McCormick, Mark Smith, Kenneth Palmer, John Lindbo, Long Nguyen, Gregory Pogue
-
Publication number: 20060134604Abstract: A plurality of proteins of interest, or peptides of interest, or other genetically expressed materials, are screened and subsequently produced using any of a variety of expression systems. The plurality of proteins are extracted from a plurality of separate, processed green juices, each green juice containing one of the proteins of interest. A multi-channel apparatus processes the various green juices, one green juice per channel. The apparatus is computer controlled such that the various valves in each channel and pump are controlled in an automated manner to extract each protein of interest and deliver each protein of interest into its own storage vessel.Type: ApplicationFiled: December 16, 2005Publication date: June 22, 2006Inventors: Mark Smith, Kenneth Palmer, Gregory Pogue, John Lindbo, Kathleen Hanley, David Mannion, Gershon Wolfe
-
Publication number: 20060018900Abstract: A polypeptide self-antigen useful in a tumor-specific vaccine mimics one or more epitopes of an antigen uniquely expressed by cells of the tumor. The polypeptide is preferably produced in a plant that has been transformed or transfected with nucleic acid encoding the polypeptide and is obtainable from the plant in correctly folded, preferably soluble form without a need for denaturation and renaturation. This plant-produced polypeptide is immunogenic without a need for exogenous adjuvants or other immunostimulatory materials. The polypeptide is preferably an scFv molecule that bears the idiotype of the surface immunoglobulin of a non-Hodgkin's (or B cell) lymphoma. Upon administration to a subject with lymphoma, the plant-produced, tumor-unique scFv polypeptide induces an idiotype-specific antibody or cell-mediated immune response against the lymphoma.Type: ApplicationFiled: August 22, 2005Publication date: January 26, 2006Inventors: Alison McCormick, Daniel Tuse, Stephen Reinl, John Lindbo, Thomas Turpen
-
Publication number: 20050282263Abstract: Herein described are various methods for making a vaccine that are made of re-assembled virus like particles (VLP). First, the VLPs are disassembled into coat proteins or encapsidation intermediate populations. Each population undergoes, for instance, chemical conjugation of unique peptide or nucleic moieties to form separate populations. Thereafter, a predetermined amount of each of the several (one or more) different coat proteins or encapsidation intermediates from the different populations is mixed and joined, forming intact VLPs, surrounding a nucleic acid core, that are composed of different coat proteins such that the reassembled VLP displays more than one peptide or other molecule. The nucleic acid can function either as a scaffold alone or can be engineered for the expression of an immunomodulatory protein in a eukaryotic cell.Type: ApplicationFiled: March 25, 2005Publication date: December 22, 2005Applicant: LARGE SCALE BIOLOGY CORPORATIONInventors: Alison McCormick, Mark Smith, Kenneth Palmer, John Lindbo, Long Nguyen, Gregory Pogue
-
Publication number: 20050175590Abstract: The present invention provides nucleic acid sequences having an altered viral movement protein and 126/183 kDa replicase proteins further characterized in its ability tostabilize a transgene contained in a virus that expresses the altered movement protein. The present invention also provides viral vectors expressing the altered movement protein, cells transformed with the vectors, and host plants infected by the viral vectors.Type: ApplicationFiled: July 21, 2003Publication date: August 11, 2005Applicant: Large Scale Biology CorporationInventors: Wayne Fitzmaurice, Gregory Pogue, John Lindbo
-
Publication number: 20050153283Abstract: We describe here an in vitro method of increasing complementarity in a heteroduplex polynucleotide sequence. The method uses annealing of opposite strands to form a polynucleotide duplex with mismatches. The heteroduplex polynucleotide is combined with an effective amount of enzymes having strand cleavage activity, 3? to 5? exonuclease activity, and polymerase activity, and allowing sufficient time for the percentage of complementarity to be increased within the heteroduplex. Not all heteroduplex polynucleotides will necessarily have all mismatches resolved to complementarity. The resulting polynucleotide is optionally ligated. Several variant polynucleotides result. At sites where either of the opposite strands has templated recoding in the other strand, the resulting percent complementarity of the heteroduplex polynucleotide sequence is increased. The parent polynucleotides need not be cleaved into fragments prior to annealing heterologous strands. Therefore, no reassembly is required.Type: ApplicationFiled: August 21, 2002Publication date: July 14, 2005Inventors: Hal Padgett, John Lindbo, Wayne Fitzmaurice
-
Publication number: 20050005319Abstract: The present invention provides methods for rapidly determining the function of nucleic acid sequences by transfecting the same into a host organism to effect expression. Phenotypic and biochemical changes produced thereby are then analyzed to ascertain the function of the nucleic acids which have been transfected into the host organism. The invention also provides methods for silencing endogenous genes by transfecting hosts with nucleic acid sequences to effect expression of the same. The present invention also provides methods for selecting desired functions of RNAs and proteins by the use of virus vectors to express libraries of nucleic acid sequence variants. Moreover, the present invention provides methods for inhibiting an endogenous protease of a plant host.Type: ApplicationFiled: July 16, 2004Publication date: January 6, 2005Applicant: LARGE SCALE BIOLOGY CORPORATIONInventors: Guy della-Cioppa, Robert Erwin, Wayne Fitzmaurice, Kathleen Hanley, Moaro Kumagai, John Lindbo, David McGee, Hal Padgett, Gregory Pogue